Background: Despite increasing evidence supporting the clinical utility of immune infiltration in the estrogen receptornegative (ER-) subtype, the prognostic value of immune infiltration for ERþ disease is not well defined. Methods: Quantitative immune scores of cell abundance and spatial heterogeneity were computed using a fully automated hematoxylin and eosin-stained image analysis algorithm and spatial statistics for 1178 postmenopausal patients with ERþ breast cancer treated with five years' tamoxifen or anastrozole. The prognostic significance of immune scores was compared with Oncotype DX 21-gene recurrence score (RS), PAM50 risk of recurrence (ROR) score, IHC4, and clinical treatment score, available for 963 patients. Statistical tests were two-sided. Results: Scores of immune cell abundance were not associated with recurrence-free survival. In contrast, high immune spatial scores indicating increased cell spatial clustering were associated with poor 10-year, early (0-5 years), and late (5-10 years) recurrence-free survival (Immune Hotspot: LR-v 2 ¼ 14.06, P < .001, for 0-10 years; LR-v 2 ¼ 6.24, P ¼ .01, for 0-5 years; LR-v 2 ¼
prognostic information provided for long-term (0-10 years) and late (5-10) recurrence varies across these tests (5, 6) .
Immune infiltration is not explicitly accounted for in any of the above tests. Increasing evidence supports the role of tumorinfiltrating lymphocytes (TILs) in influencing disease progression and treatment response in breast cancer (7) (8) (9) (10) . Characterization of the nature of immune responses is key to understanding tumor immunity and empowering immunotherapy. However, the majority of reports focus on ER-and human epidermal growth factor receptor 2-positive (HER2þ) breast cancers, where extensive immune infiltration is more common and immune scores were found to be highly predictive of survival and response to chemotherapy (8, (11) (12) (13) (14) (15) . In contrast, there is a lack of definitive data on the prognostic value of immune scores in ERþ breast cancer following endocrine treatment (7, 16) . A major reason for this is the absence of reproducible scoring methods to facilitate large-scale studies of ERþ breast cancer. This also limits the translation of immune scoring into clinical advances.
We have developed quantitative and reproducible approaches to score lymphocytic infiltration (LI) in breast cancer, based on fully automated image analysis of routinely generated hematoxylin and eosin (H&E)-stained histology sections. Quantitative immune scores of overall LI in tumors, as well as intratumor lymphocyte ratio (ITLR), were associated with good survival in ER-and ER-/HER2-breast cancer (17, 18) . In addition, our automated image analysis scheme enables the study of complex spatial patterns of TILs (19) . The spatial interactions among TILs and cancer cells generate complex ecological dynamics that can ultimately impact tumor progression and response to treatment (8, (20) (21) (22) . In this study of 1178 postmenopausal breast cancer patients with ERþ disease, patients enrolled in the Arimidex or Tamoxifen Alone or Combined (ATAC) trial, our aims were to 1) establish the prognostic value of H&E-based, quantitative scores of TIL abundance as well as spatial heterogeneity for 10-year, early recurrence (0-5 years) and late recurrence (5-10 years) after endocrine therapy; 2) compare their prognostic value with established prognostic tests including RS, ROR, IHC4, and CTS; 3) evaluate a new histology-based model that combines IHC4 and immune scores as a cost-effective biomarker.
Methods

Study Population
Classical clinicopathologic factors (age, nodal status, tumor size, grade, randomized treatment) were collected from patients with ERþ primary breast cancer in the ATAC trial who were randomly assigned to either anastrozole or tamoxifen (Supplementary Table  1 , available online) (23) . A total of 1178 eligible patients who did not receive chemotherapy and from whom H&E-stained slides from formalin-fixed, paraffin-embedded tissues were available were included (Figure 1 ). Of these, 963 patients were scored with prognostic scores including IHC4, RS, ROR46, and CTS (Table 1) .
A total of 1037 tumors were HER2-, 909 of which were scored with prognostic scores. A subset of 91 TransATAC samples were randomly selected and scored on H&E sections according to international recommendations (24) by a histopathologist (KN). Baseline demographics and clinical characteristics for all patients included in this analysis are provided in Supplementary Table 1 (available online) . This study was approved by the South-East London Research Ethics Committee, and all patients included gave informed consent.
H&E Image Analysis and Validation
We curated a digital database of H&E histology slides for TransATAC and applied our histology image analysis pipeline (Supplementary Figure 1A , available online) (17) . In brief, the image analysis pipeline exploits the nuclear morphological differences among cancer cells, lymphocytes, and stromal cells to differentiate them in H&E histological tissue sections. Cancer cell nuclei are generally large in size and demonstrate greater variability in appearance as compared with lymphocyte and stromal cell nuclei; lymphocyte nuclei are typically small, round, and homogeneously basophilic, and nuclei of stromal cells including fibroblasts and endothelial cells are more elongated. The pipeline consisted of four stages: 1) unsupervised segmentation of the nuclei; 2) supervised classification of individual cell nuclei into cancer, lymphocyte, other cell nuclei, and artefacts; 3) kernel smoothing to correct local sporadic errors; and 4) a hierarchical multiresolution model fitting to identify cancer cell clusters to further improve classification accuracy. The classifier was previously validated in molecular taxonomy of breast cancer international consortium (METABRIC) to have an overall accuracy of 90.1% and a high correlation between image analysis and pathological scores in the entire cohort (17) .
To evaluate the accuracy of our image analysis pipeline for TransATAC, a test set of 627 cells randomly sampled from three images was annotated by a pathologist (DNR) blinded to image analysis results (Supplementary Figure 1A , available online). Accuracy rates for identifying the three cell types were 93.8% for cancer cells, 87.9% for lymphocytes, and 84.2% for stromal cells (Supplementary Figure 1B , available online). The balanced accuracy rates as the average for sensitivity and specificity for the three cell types were 0.864 for cancer, 0.839 for lymphocytes, and 0.876 for stromal cells (Supplementary Figure 1C, 
Automated Scoring of Immune Cell Abundance and Spatial Heterogeneity
Immune cell abundance scores include Lymphocytic Infiltration (LI), which summarizes the fraction of lymphocytes in all cells in the tumor section; and Intratumor Lymphocyte Ratio (ITLR), Adjacent-to-Tumor Lymphocyte Ratio (ATLR), and Distal-ToTumor Lymphocyte Ratio (DTLR), which are defined as the number of specific types of lymphocytes normalized by the number of cancer cells (17, 18) . Intratumor Lymphocytes (ITLs), Adjacent-toTumor Lymphocytes (ATLs), and Distal-To-Tumor Lymphocytes (DTLs) were identified using unsupervised clustering based on their spatial proximities to cancer cells, which was quantified using a kernel density method on the distribution of cancer cells.
Immune cell spatial scores quantify the amount of spatial clusters, or hotspots, formed by lymphocytes and/or cancer cells within the section (Figure 2 ) (13). Getis-Ord spatial analysis was carried out to identify tumor regions with statistically significant spatial clustering of immune cells, that is, immune hotspots. This means that the frequency of immune cells appearing at these locations is greater than expected by chance given the distribution of all cells in the entire tumor section and that, importantly, the difference between the actual and expected value is statistically significant. A P value was ARTICLE computed for each spatial region, which can be used to determine statistical significance using a significance level of .05. Previously, tumors with a high amount of regions that are both immune hotspots and cancer hotspots (immune-cancer hotspots) were found to have good prognosis in ER-cancer (13) . Here for comparison in ERþ breast cancer, Cancer Hotspot and Immune Hotspot scores that examine only one type of cell at a time were also included. For validation of the intercorrelations among immune scores, H&E-stained, whole-section images of 743 ERþ, treatment-naïve primary tumors from the METABRIC study (25) were analyzed using the same methods. All patient specimens were obtained with appropriate ethical approval from the relevant institutional review boards.
Statistical Analyses
Our primary objective was to assess whether immune scores had statistically significant prognostic information for predicting 10-year recurrence in postmenopausal women with breast cancer given either tamoxifen or anastrozole monotherapy but not chemotherapy. Secondary analyses included determining the prognostic ability of immune scores in predicting early (0-5 years) and late recurrences (5-10 years) in patients divided into subgroups by HER2 status, and the additional prognostic information provided by tests in multivariable comparisons including age (<65, !65 years), nodal status (0, 1-3, 4þ), tumor size ( 1 cm, >1 to 2 cm, >2 to 3 cm, >3 cm), central read grade added to the IHC4 score. Sample splitting was used, in which the immune score was dichotomized by using half the data as the training set, and then the cutoff points for each score were evaluated in the remaining half of the data as the validation set. Because the use of optimizing cutoffs may lead to overestimation of prognostic power, dichotomized variables were only used for analysis presented in Figure 2 , B-D, and continuous variables were used elsewhere. For measuring correlation among immune scores and with pathological TIL scores, Spearman's correlation was used. All statistical analyses were performed using STATA version 13.1 or R version 3.3.1. All statistical tests were two-sided, and a P value of less than .05 was considered statistically significant.
Results
Correlations Among Immune Scores
Four immune abundance scores (overall Lymphocytic Infiltration, Intratumor Lymphocyte Ratio, Adjacent-to-Tumor Lymphocyte Ratio, and Distal-To-Tumor Lymphocyte Ratio) and three spatial scores (Immune Hotspot, Cancer Hotspot, Immune-Cancer Hotspot) were calculated based on fully automated histology image analysis on whole-section slides ( Figure 2 , Table 1 ). There was a strong, negative correlation between ITLR and DTLR (r ¼ -0.888) ( Figure 2 , available online).
Prognostic Value of Immune Scores
None of the immune abundance scores provided significant prognostic information for recurrence (P > .1). In contrast, high spatial scores were associated with poor recurrence-free survival across 10 years in the univariate analysis (Immune Hotspot: n ¼ 1178, LR-v 2 ¼ 14.06, P < .001) ( (Table 3) . None of the patients in this study received trastuzumab if their tumors were HER2þ, as is current practice. In the HER2-population (n ¼ 1037), again spatial scores but not abundance scores were prognostic for all time windows (Table 3 ). In the multivariable analysis, spatial scores were prognostic for all time windows except for Immune Hotspot and Immune-Cancer Hotspot for early recurrence (Table 3) . We henceforth focused on spatial scores only.
Comparison of Immune Spatial Scores With RS, IHC4, ROR, and CTS
The prognostic value of spatial scores for late recurrence (5- .84) or was as prognostic as ROR and CTS in any time window (Figure 3) . We then examined the additional prognostic value of spatial scores to IHC4 and RS for 0 to 10 years and late recurrence. Immune-Cancer Hotspot provided statistically significant prognostic value when added to IHC4 and RS for years 0 to 10 whereas Immune Hotspot also added prognostic value to IHC4 and RS for late recurrence (DLR-v 2 > 3.84) ( Table 4 ). Cancer Hotspot, on the other hand, added prognostic information to IHC4 and RS in both time windows (Table 4 ). In the HER2-population, Immune Hotspot and Immune-Cancer Hotspot added statistically significant prognostic information to IHC4 and RS in both time windows (Table 4) . Again, Cancer Hotspot added statistically significant information to IHC4 and RS in both time windows (Table 4) .
However, none of the spatial scores provided prognostic information beyond that of CTS or ROR in the HER2-or the overall population (DLR-v 2 3.84).
IHC41Immune Spatial Score
To evaluate a new biomarker based entirely on histology slides, we sought to determine the prognostic value of a combined model of IHC4 and spatial scores for 0 to 10 years and late recurrence. The prognostic value of IHC4 and that of RS are similar in the two-time windows and populations (DLR-v 2 3.84). For predicting recurrence across 10 years, Cancer Hotspot combined with IHC4 achieved a better performance than RS alone in both cohorts (overall population: DLR-v 2 ¼ 9.23; in HER2-: DLR-v 2 ¼ 6.54) (Figure 3 ). For predicting late recurrence, prognostic value higher than RS was observed for IHC4 combined with any of the spatial scores in both populations, except for Immune-Cancer Hotspot in the overall population ( Figure 3 
Discussion
In this study, we aimed to establish the prognostic value of immune scores for recurrence in ERþ breast cancer patients treated with anastrozole or tamoxifen. While immune response and immunotherapy for ER-diseases have been under the spotlight, correlation of TILs with outcomes in ERþ disease is less clear (16) , with many studies reporting the lack of statistically significant prognostic association (11, 15, 26, 27) . In line with these reports, we did not find prognostic value in immune abundance scores that only account for the amount of TILs in the entire histology section or in specific tumor regions including intratumor, adjacent tumor, and distal tumor, as scored by digital histology slide image analysis. In contrast, our immune scores based on the spatial heterogeneity of TILs were highly prognostic, particularly for late recurrence after five years of endocrine therapy. This suggests a lasting memory of tumor immunity on disease progression and evolution of treatment resistance in ERþ cancer. Such spatial heterogeneity may reflect spatial distribution patterns of different immune cell subsets.
Intratumor heterogeneity of cancer cells may also in turn influence immune spatial distribution through cytokine secretion and neoantigen presentation. While the biological mechanisms remain to be investigated, our finding has clinically significant implication, which suggests that TILs have been previously overlooked in ERþ diseases because of the lack of in-depth analysis of TILs on the tissue spatial organization level. Our findings highlight the importance of examining not just cell abundance but also spatial patterns that can be indicative of immune functional phenotypes and disease prognosis. In contrast to our observation in ER-tumors (13), high Immune-Cancer Hotspot score, indicating increased spatial clustering in immune and cancer cells, correlated with poor prognosis in ERþ breast cancer. However, this is consistent with our previous finding that immune gene signature was associated with poor response to endocrine therapy in a neoadjuvant setting (28, 29) . The difference may be due to immune composition and functionality in the two subtypes and mechanisms by which immune response contributes to hormonal therapy resistance (30, 31) . In a recent study of immune composition in 7270 breast cancers, a higher fraction of T-regulatory cells and M2 macrophages and a lower fraction of M1 macrophages were found in ERþ compared with ER-cancers (12) . Therefore, compared with ER-subtype, the immune landscape of the ERþ subtype is characterized by increased T-cell regulation and macrophage polarization toward protumorigenic M2, which is consistent with our results.
ARTICLE
Strengths of this study include the large patient cohort with long-term follow-up systematically collected in a welldocumented clinical trial, well-characterized samples that enable a direct comparison with established biomarkers, and fully automated and reproducible methods for immune scoring. These allowed us to evaluate quantitative immune scoring based entirely on H&E-stained tumor slides, which are readily generated as part of clinical routine. Comparison of the automated immune scores with a pathologist's score following recommendations for TIL evaluation in breast cancer (24) in a subset of samples showed a weak correlation overall. This is, however, unsurprising when one considers that the automated scores include regions of the tumor that are excluded on pathological evaluation. Indeed, the latter includes stromal TILs only, which are assessed as percentage surface area that is inflammatory as opposed to fibroblastic (25) . In contrast, the automated scores count either the absolute number of lymphocytes in relation to cancer cells or the frequency of (co-)clustering of immune and cancer cells. Thus, the information gleaned from these methods potentially provides different biological information about the interaction between these cell types, and, as demonstrated herein, can provide valuable prognostic information. Developing a histology-based test as such thus has the advantages of cost-effectiveness and general applicability. The prognostic value of immune scores for late recurrence is similar to that of IHC4 and RS, which is the most widely used test for residual risk of recurrence following surgery and endocrine. Although they did not add prognostic value to CTS, in almost all occasions immune scores add prognostic information to the individual components that make up CTS, including node status, size, grade, age, and treatment. Because CTS was developed and optimized using TransATAC samples (4), the independent prognostic value of immune scores remains to be validated in further endocrine adjuvant therapy studies with homogeneous treatments such as POETIC (32) . In addition, the strong prognostic value of CTS and ROR could be partly explained by the use of tumor size in their calculation, which is a highly prognostic factor. Furthermore, IHC4 combined with immune score is statistically significantly more prognostic than RS, particularly for late recurrence. The clinical utility of IHC4þ immune scores as a combined histology-based test is well worth exploring. 
Weaknesses of our study include the use of a single histology slide per tumor, such that intratumor heterogeneity cannot be fully addressed, and the lack of immune markers that may provide further insights into immune functions in ERþ disease and better predictors due to little residual tissue available. In addition, whether our methods can sufficiently address challenges arising from variability in factors that include fixation, staining, and acquisition in a clinical setting needs to be evaluated before implementation. Our results also only apply to women who are chemotherapy-free.
Furthermore, our study also provides relevant information for new treatment strategy in the high-risk ERþ population identified by immune scores. Our findings support different immunosuppressive mechanisms in the ERþ and ER-subtypes, and in light of these results call for the development of novel cancer therapeutics targeting the pathways that reverse these mechanisms specifically for ERþ disease. This may also help explain why anti-PD1 checkpoint inhibition, despite demonstrating activity as monotherapy in early-phase trials in ERþ breast cancer, had low response rates compared with triple-negative breast cancer and was highly variable among trials (33, 34) . Further, we speculate that immune scores may be useful as predictive biomarkers for immunotherapy, given the limited clinical utility of PDL1 expression in guiding patient selection (35) .
In summary, enabled by fully automated image analysis of histology sections, our study provided an additional dimension to the analysis of immune functional phenotype in breast cancer. Spatial data provided by histology, once quantitatively analyzed, will aid the identification of clinically relevant features, potentially yielding predictions more powerful than measurements of cell abundance that ignore the spatial context. 
